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5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used
to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and
other malignancies. 5-AZA-CdR can reactivate tumor suppressor genes silenced by aberrant DNA methylation, a
frequent event in all types of cancer. Because this epigenetic change is reversible, it is a good target for 5-AZA-CdR
therapy. We have reviewed the preclinical data of 5-AZA-CdR to analyze the concentrations and exposure times
required to eradicate cancer stem cells. We analyzed the dose-schedules used in animal models that show potent
antineoplastic activity of 5-AZA-CdR. We attempted to correlate the preclinical data with the responses obtained in
clinical trials of 5-AZA-CdR in patients with cancer. The pharmacokinetics and drug distribution of 5-AZA-CdR are
key parameters because adequate therapeutic drug levels are required to eliminate cancer stem cells in all
anatomic compartments. The plasma half-life of 5-AZA-CdR in humans is approximately 20 minutes due to the high
levels in the liver of cytidine deaminase, the enzyme that inactivates this analogue. This provides a rationale to use
an inhibitor of cytidine deaminase in combination with 5-AZA-CdR. Low-dose 5-AZA-CdR is effective for MDS and
AML and can induce complete remissions (CR). However, maintenance of CR with low-dose 5-AZA-CdR is difficult.
Based on analyses of preclinical and clinical data, low dose 5-AZA-CdR has the potential to be an effective form of
therapy in some patients with cancer. For patients who do not respond to low dose therapy we recommend
dose-intensive treatment with 5-AZA-CdR. Patients who are candidates for intensive dose 5-AZA-CdR should have a
good bone marrow status so as to permit adequate recovery from myelosuppression, the major toxicity of 5-AZA-CdR.
Solid tumors are also interesting targets for therapy with 5-AZA-CdR. Both low dose and intensive therapy with
5-AZA-CdR can reduce the proliferative potential of tumor stem cells in animal models. We propose novel dose
schedules of 5-AZA-CdR for investigation in patients with cancer. The full chemotherapeutic potential of 5-AZA-CdR to
treat cancer merits further clinical investigation and can only be realized when its optimal dose-schedule is determined.
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PharmacodynamicsIntroduction
5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine) was
first synthesized in 1964 by Pliml and Sorm [1] and its
potential activity in leukemia was reported in 1968 by
Sorm and Vesely [2]. 5-AZA-CdR is an analog of the
natural nucleoside 2′-deoxycytidine in which the carbon* Correspondence: richard.l.momparler@umontreal.ca
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Preclinical studies in rodents indicated that 5-AZA-CdR
is a more potent antileukemic agent than cytosine arabi-
noside (ARA-C) [3,4]. In 1979, Taylor and Jones [5]
reported that 5-AZA-CdR could induce cells in culture
to differentiate into different phenotypes and this activity
correlated with its inhibition of DNA methylation. The
first review on the pharmacologic properties of 5-AZA-
CdR was published in 1979 [6] and the first clinical trial
on 5-AZA-CdR in patients with acute leukemia was
published in 1981 [7].Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Intracellular metabolism of 5-AZA-CdR. 5-AZA-CdR is
transported into the cell by the equilibrative-nucleoside transport
system. 5-AZA-CdR converts into its triphosphate form by
phosphorylation and binds covalently to the DNA, where it
blocks DNMTs and causes demethylation of DNA. 5-AZA-CdR,
5-aza-2′-deoxycytidine; DNMTs, DNA methyltransferases.
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CdR has been known for many years, its approval for the
treatment of cancer took a long time, perhaps due to a
lack of understanding of the importance of epigenetic
changes in malignancy during the early years of develop-
ment [8]. 5-AZA-CdR was approved for the treatment of
myelodysplastic syndrome (MDS) in 2006 and shows anti-
leukemic activity against acute myeloid leukemia (AML)
as well [8,9]. Its clinical activity against solid tumors is
under investigation. 5-AZA-CdR also displays some effect-
iveness in the treatment of sickle cell disease, which is
nonmalignant [10]. Low-dose 5-AZA-CdR was proposed
to be effective for treating MDS due to its epigenetic
action, whereas higher doses were too toxic due the poor
hematologic status of these patients [11]. The objectives of
this review is to analyze preclinical and clinical data on
5-AZA-CdR and develop a rationale for optimization of
its dose schedule for the treatment of cancer.
Review
Mode of action and cellular metabolism
Recent progress on elucidating the important role of epi-
genetics in the development of malignancy has generated
more interest in the chemotherapeutic potential of 5-AZA-
CdR for the treatment of cancer [12,13]. ‘Epigenetics’ refers
to the study of heritable changes in gene expression that
occur without changes in the DNA sequences [14]. Epi-
genetic regulation of gene expression is modulated by
changes in DNA methylation, covalent histone modifica-
tions, and microRNA [15-17]. Hypermethylated tumor
suppressor genes represent one of the most consistent
hallmarks of human cancers [12,18]. Loss of the expres-
sion of tumor suppressor genes can lead to a loss of regu-
lation of cancer cell growth [19-21].
DNA methylation usually occurs at the 5-position of
the cytosine ring within cytosine-phosphate-guanine
(CpG) dinucleotide by a transfer of the methyl group
from S-adenosyl-L-methionine [22]. DNA methyltrans-
ferases (DNMTs) catalyze this reaction. The methyla-
tion pattern from the parental DNA is copied onto the
newly synthesized DNA strand by the maintenance
methyltransferase DNMT 1. In embryonic stem cells and
tumor cells, methylation of previously unmethylated DNA
(de novo methylation) is catalyzed by DNMT 3a or DNMT
3b [23]. To inactivate transcription, methylation usually
occurs in the CpG islands in the promoter-exon regions of
target genes. Half of all genes harbor CpG islands in their
promoters [24]. In human DNA, approximately 50% to
70% of CpG dinucleotides are methylated [25,26]. During
normal embryonic development, cytosine methylation is
essential for establishing tissue-specific gene expression, si-
lencing imprinted genes, and inactivating the X chromo-
some. Methylation also protects against the transcription
of parasitic elements [27].Both 5-AZA-CdR and 5-azacytidine have been reported
to inhibit the expression of the de novo DNA methylating
enzymes, DNMT3B [28,29]. DNMT3A-DNMT3B double
null embryonic stem cells are highly resistant to 5-AZA-
CdR as compared to single null or wild type cells [30].
Mutations in DNMT3A have been identified in AML and
MDS [31,32]. These DNMT3A mutations are associated
with a poor outcome for both AML and MDS patients. A
recent report showed that DNMT3A plays a role in silen-
cing self-renewal genes in hematopoietic stem cells so as to
permit hematopoietic differentiation [33]. Preliminary data
indicate that AML patients with low DNMT3A activity
may benefit from treatment with 5-AZA-CdR [34]. The full
role of DNMT3A and DNMT3B in leukemogenesis still
remains to be clarified.
5-AZA-CdR is a prodrug that must be activated by phos-
phorylation. The metabolism of this analog is summarized
in Figure 1. Due to the function of the nucleoside transport
system, 5-AZA-CdR rapidly reaches its equilibration state
between the extracellular and intracellular compartments,
as indicated by the short alpha half-life of five minutes [35].
The cellular uptake of the drug is realized by an equili-
brative nucleoside-specific transport mechanism [36-39],
which is followed by phosphorylation and incorporation
of the drug into DNA, resulting in potent inhibition of
DNMT.
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deoxycytidine kinase to its monophosphate form and by
other kinases to its triphosphate form, which is then incor-
porated into DNA by DNA polymerase [5,40-43]. The in-
hibition of DNA methylation is due to formation of a
covalent complex between 5-AZA-CdR-DNA and DNMT1
at CpG methylation sites, resulting in the inactivation of
this enzyme [44,45]. DNMT1 inhibition results in DNA
hypomethylation, gene activation and the induction of cel-
lular differentiation, senescence, and/or apoptosis [40-42].
5-AZA-CdR does not block the progression of G1-
phase cells into S-phase [46]. Flow cytometry investiga-
tions revealed that 5-AZA-CdR slows the progression of
cells into S-phase, but it does not block cell progression
through their cycle [47], unlike the related nucleoside
analogs 5-azacytidine and ARA-C [48]. One of the key
biochemical markers of 5-AZA-CdR is the p15 tumor
suppressor gene, which is frequently hypermethylated in
MDS and AML patients and can be reactivated by this
analog [49]. Table 1 summarizes key genes that are
silenced by DNA methylation in different types of cancer
as published in the review by Esteller [15].
In vitro antineoplastic action
Leukemia
In vitro studies of 5-AZA-CdR demonstrate that it
induces differentiation, apoptosis, and senescence in
leukemic cells [40-42,50-52]. One proposed mechanism of
this action is that 5-AZA-CdR exposure reduces the ex-
pression of c-myc, an oncogene that prevents the terminal
differentiation of cells [53]. 5-AZA-CdR also maintains
hematopoietic precursor self-renewal [54]. Leukemic cells
can undergo phenotypic modification after exposure to
5-AZA-CdR, as indicated by the increased expression of
several antigen markers [55,56]. 5-AZA-CdR enhances the
graft-versus leukemia effect, which has the potential toTable 1 Silencing by DNA methylation of key genes in
different types of cancera
Genes Type of cancer
p16, p14, RARβ2, SFRP1 Colon cancer
p16, p14 Esophageal cancer
p14, hMLH1 Stomach cancer
SOCS1, GSTP1 Liver cancer
ER, BRCA1, E-cadherin, TMS1 Breast cancer
BRCA1 Ovarian cancer
GSTP1 Prostate cancer
p16, DAPK, RASSFIA Lung cancer
p16, TPEF/HPP1, miR-127 Bladder cancer
VHL Kidney cancer
p15, EST1, ID4 Leukemia
p16, p73, MGMT Lymphoma
amodified from Esteller M. [15]. p16, p16INK4a; p14, p14ARF; p15, p15INK4b.increase the immunologic therapeutic efficacy of allogen-
eic transplantation [57]. 5-AZA-CdR also induces the
upregulation of DNA repair genes and angiogenesis in-
hibitor genes [58]. These changes can suppress the devel-
opment of malignancy. In vitro studies of 5-AZA-CdR also
illustrate its potent antileukemic activity [59,60]. At equi-
molar concentrations, 5-AZA-CdR more potently reduces
colony formation than either 5-azacytidine or ARA-C [61].
5-AZA-CdR also has greater DNA-hypomethylating activ-
ity than 5-azacytidine [61]. In vitro studies on the induction
of the loss of clonogenicity by 5-AZA-CdR on human
leukemic cell lines of different phenotypes are summarized
in Table 2. The 50% inhibitory concentration (IC50) of col-
ony formation for a one-hour exposure to 5-AZA-CdR
was approximately 10 μM for HL-60 (myeloid), Molt-3
(T-cell) and RPMI-8392 (B-cell) leukemic cell lines. For a
24-hour exposure, the IC50 of 5-AZA-CdR is in the range
of 0.1 μM for these leukemic cell lines. This observation
illustrates the importance of the duration of treatment with
respect to the antileukemic activity of 5-AZA-CdR.
In solid tumors
Several studies on different type of tumors demonstrated
an association between DNA hypermethylation and
DNMT overexpression [62-64]. The precise molecular
mechanism of aberrant DNA methylation, however,
remains to be clarified. The first tumor suppressor gene
found to undergo silencing as a result of promoter
methylation was the Rb gene in retinoblastoma tumors,
followed by numerous other tumor suppressor genes
[65-67]. 5-AZA-CdR reactivates many genes that sup-
press malignancy and are silenced by aberrant DNA
methylation in solid tumors (Table 1). 5-AZA-CdR reac-
tivates the tumor suppressor gene VHL in human renal
carcinoma cell lines and the expression of the p16/
CDKN2 tumor suppressor gene, which prevents the
entry of tumor cells into the S-phase of the cell cycle, in
different tumor cell lines [20,68-72]. The mRNA expres-
sion of the p53 gene increases in hepatoma cell lines afterTable 2 In vitro concentrations of 5-AZA-CdR that
eradicate the proliferative potential of leukemic cells
Leukemic cell lines IC50 Duration of
exposure
References
HL 60 (myeloid) 100 μM 1 hour [59]
Molt-3 (T-cell) 10 μM 1 hour [59]
RPMI 8392 (B-cell) 10 μM 1 hour [59]
HL60 leukemic cells 0.05 to 0.1 μM 24 hours [60]
L1210 leukemic cells 0.075 μM 18 hours [60]
Molt-3 (T-cell) about 0.1 μM 24 hours [59]
HL 60 (myeloid) about 0.1 μM 24 hours [59]
RPMI 8392 (B-cell) about 0.1 μM 24 hours [59]
1 μM = 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; IC50, half maximal
inhibitory concentration.
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a mismatch repair gene that confers chemoresistance to
certain anticancer agents, is reactivated by 5-AZA-CdR in
ovarian and colon cancer cell lines [74,75]. 5-AZA-CdR
reactivates CDKN2a (p16INK4a) in lung cancer, BRCA1
in breast cancer, and MGMT in glioblastomas [76-79].
Expression of unmethylated genes, such as Apaf-1 and
CDKN2D in malignant melanoma and lung cancer, is
enhanced after 5-AZA-CdR treatment, indicating that
gene activation can occur by indirect mechanisms [80,81].
5-AZA-CdR reduces natural killer cell responsiveness,
which may be used in therapeutic strategies to target ma-
lignant cells by an immune mechanism [82].
Preclinical studies using colony assays indicate that
5-AZA-CdR is an active antineoplastic agent against
many different tumor cell lines [60,83-88]. These stud-
ies demonstrated that the demethylation of genes
involved in cell cycle control inhibits the growth of
various tumors [66,79,89]. The in vitro studies on the
antineoplastic activity of 5-AZA-CdR in tumor cell
lines are summarized in Table 3. For example, the
IC50 is approximately 4 μM for a two-hour exposure
in fibrosarcoma cells and approximately 0.5 μM for a
four-hour exposure in Calu-6 lung carcinoma cells
[60,88]. For a 48-hour exposure, the IC50 is in the
range of 0.1 μM for different tumor cell lines (Table 3).
As observed with leukemic cells, the duration of treat-
ment is a key factor with respect to the antineoplastic
activity of 5-AZA-CdR.
In vivo antineoplastic action
The antineoplastic activity of 5-AZA-CdR was first
demonstrated in mouse models of acute leukemia [2]. InTable 3 In-vitro concentrations of 5-AZA-CdR that
eradicate proliferative potential of solid tumor cells
Tumor cell lines IC 50 Duration of
treatment
References
HS-SY-II synovial sarcoma 1.3 μM 96 hours [84]
SYO-1 synovial sarcoma 0.9 μM 96 hours [84]
KB oropharyngeal cancer 0.5 μM 96 hours [85]
A549 lung adenocancer 0.49 μM 96 hours [85]
LoVo colon cancer 0.4 μM 96 hours [85]
LoVo-DX colon cancer 0.1 μM 96 hours [85]
MDA-MB- 435 breast cancer 0.2 μM 48 hours [83]
Hs578T breast cancer 0.13 μM 48 hours [87]
MCF-7 breast cancer 0.13 μM 48 hours [87]
MDA-MB- 231 breast cancer 0.013 μM 48 hours [83]
EMT6 mammary cancer 0.22 μM 18 hours [60]
Calu-6 lung cancer 0.44 μM 4-8 hours [60]
A(T1)C1-3 fibrosarcoma 4.38 μM 2 hours [88]
1 μM= 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; IC50, half maximal
inhibitory concentration.mice with murine L1210 leukemia, the activity of 5-AZA-
CDR markedly increases with an increased dose and ex-
posure time [60,61]. In a preclinical study using the L1210
mouse leukemia model, the curative dose of 5-AZA-CdR
administered as a 15-hour infusion was 20 mg/kg. The
antileukemic activity of 5-AZA-CdR, 5-azacytidine, and
ARA-C was compared in the L1210 leukemia mouse
model [61]. The mice were administered these nucleoside
analogs in a 15-hour continuous intravenous (i.v.) infusion
to obtain an effective plasma concentration of the drug
that persisted longer than the cell cycle of these leukemia
cells (12 hours). At equitoxic doses, 5-azacytidine (11.7
mg/kg) increased the life span of the mice by 63%,
whereas 5-AZA-CdR (10.1 mg/kg) increased the life span
of the mice by 384%. At higher doses, 5-AZA-CdR cured
the mice of leukemia, but 5-azacytidine or ARA-C did
not. Because the cell cycle of L1210 leukemic cells is
around 12 hours in duration, the 15-hour infusion of these
analogs was predicted to produce 100% cell kill in this
mouse model because all of the leukemic cells entered
S-phase during the treatment. Analysis of the surviving
leukemic cells revealed that they were not resistant to
ARA-C.
In a rat model of myeloid leukemia, 5-AZA-CdR
increased survival in a dose-related manner [4]. In this
model, the antileukemic action of 5-AZA-CdR exceeded
that of ARA-C. The hematologic toxicity of 5-AZA-CdR
was evaluated in this rat model by the colony forming unit
in the spleen (CFU-S) assay [4]. The maximum number of
hematopoietic stem cells killed at high doses of 5-AZA-
CdR was the same as that at low doses, indicating that the
response reaches a plateau upon dose escalation. This is
solid evidence that normal resting hematopoietic stem
cells survive high-dose treatment with 5-AZA-CdR. The
difference between hematopoietic stem cell toxicity
and antileukemic effects favors treatment with high
doses of 5-AZA-CdR because the dose that causes
maximal leukemic cell kill is not more toxic to resting
hematopoietic stem cells.
5-AZA-CdR displays significant antineoplastic activity
against tumors in a mouse model. In mice bearing EMT6
mammary tumors, 5-AZA-CdR at a dose of 15 mg/kg
produces a 2-log reduction in clonogenic survival as
measured by excision of the tumor, preparation of a
single-cell suspension and analysis of survival by in vitro
colony formation [60]. A higher dose of 30 mg/kg pro-
duces a 3-log reduction in clonogenic survival. These
observations illustrate the effectiveness of intensive doses
of 5-AZA-CdR for tumor therapy.
Pharmacokinetics of 5-AZA-CdR
Methods used to determine concentrations of 5-Aza-CdR
Several methods are used to determine 5-AZA-CdR
concentrations, including bioassays, HPLC, and HPLC
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these methods, HPLC/MS is the most sensitive followed
by bioassays; both of these methods are superior to HPLC
alone for detecting low concentrations of 5-AZA-CdR.
The lower limit of detection of 5-AZA-CdR is in the range
of 0.01 μM. For pharmacokinetic studies, HPLC/MS is the
method of choice for detecting the plasma concentration
of 5-AZA-CdR followed by the bioassay and HPLC meth-
ods (Table 4) [7,36,90-92].
Pharmacokinetic data
The moderate chemical instability of 5-AZA-CdR is im-
portant and dependent on both temperature and pH
[93]. Therefore, this agent must be carefully formulated.
The instability is due to the opening of the 5-azacytosine
ring between positions 5 and 6 to form N-(formylamidino)-
N′-β-D-2-deoxyribofuranosylurea (NFDU). This reaction is
highly reversible in favor of 5-AZA-CdR and results in a
minimal loss of pharmacologic activity. When NFDU
decomposes irreversibly via loss of the formyl moiety to
form N′-β-D-2-deoxyribofuranosyl-3-guanylurea (DGU),
there is a complete loss of pharmacologic activity. This re-
action occurs rapidly in alkaline solutions and increases
with elevation of the temperature. At 24°C, the 50% de-
composition rates (D50s) of 5-AZA-CdR to DGU at pH
7.0 and 8.5 are 22 hours and 5 hours, respectively. At
37°C, the D50s at pH 7.0 and 8.5 are 12hours and 2 hours,
respectively. At 5°C and pH 7.0 to 7.4, the decomposition
of 5-AZA-CdR to DGU is minimal (<1%). To formulate
5-AZA-CdR, we recommend using 5 to10 mM potassium
phosphate, pH 7.0 to 7.4 and storage at 5°C until clinical
use. A fresh solution of 5-AZA-CdR can be prepared
every eight hours. During the infusion of 5-AZA-CdR to
patients, we recommend using an ice pack to maintain the
temperature at 10°C [93]. After i.v. administration of
5-AZA-CdR, its binding to plasma protein is less than 1%.
There is a rapid distribution of 5-AZA-CdR between the
extra- and intracellular compartments after i.v. injection,
as indicated by its alpha half-life of five minutes [35].
5-AZA-CdR penetrates the blood–brain barrier. The level
of 5-AZA-CdR in the cerebrospinal fluid (CSF) reaches as
high as 50% of its plasma level during a continuous infusionTable 4 Comparison of methods to determine
concentration of 5-AZA-CdR
Method Limit sensitivity for detection References
Bioassay 5 nM [7]
6 nM [36]
HPLC 750 nM [90]
HPLC/MS 10 nM [91]
5 nM [92]
1 μM = 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; HPLC, high
performance liquid chromatography; HPLC/MS, Hjgh performance liquid
chromatography/mass spectrometry.[35]. The beta plasma half-life of 5-AZA-CdR in adults is
approximately 15 to 25 minutes due to very high levels of
cytidine deaminase in the human liver and spleen [94,95]
In pediatric populations, the beta half-life is 10 to 15 min-
utes, which is shorter than that of adults, probably due to
the higher cytidine deaminase activity in the liver and
spleen of children [7,90]. Repeated administration of
5-AZA-CdR in patients with MDS as a 3-hour infusion of
15 mg/m2 every eight hours for three days does not result
in systemic accumulation of the drug, and the pharmaco-
kinetic parameters remain unchanged from cycle to cycle
[92]. An illustration of the plasma pharmacokinetics of
the dose schedule that is currently used to treat MDS and
AML is shown in Figure 2. 5-AZA-CdR is cleared from
the systemic circulation rapidly. 5-AZA-CdR is inactivated
primarily through deamination by cytidine deaminase
in the human liver and spleen [94,95]. The half-life of
5-AZA-CdR is related to the blood flow into the liver. Its
clearance exceeds the total renal capacity, which suggests
an important role of non-renal elimination. The clearance
rate has been reported as approximately 125 ± 20 ml/min/
kg [36]. The urinary excretion of unchanged 5-AZA-CdR
is low, typically <1% of the total dose given to the patients
[36]. Oral formulations of 5-AZA-CdR are currently
under investigation [96]. The pharmacokinetic parameters
of 5-AZA-CdR are summarized in Table 5.
5-Aza-CdR in the treatment of hematologic malignancies
5-AZA-CdR was first used as a single agent in a phase
I study in children with relapsed or refractory acuteFigure 2 Pharmacokinetics of 5-AZA-CdR at a dose of 15 mg/
m2 as a three-hour i.v. infusion to patients with AML and MDS
[92]. After i.v. infusion of 5-AZA-CdR, it reaches a steady-state
plasma level within two hours, confirming its very short half-life.
5-AZA-CdR, 5-aza-2′-deoxycytidine; AML, acute myeloid leukemia; i.v.,
intravenous; MDS, myelodysplastic syndrome.








Bioassay[36] 25 to 100 mg/m2 1
hour inf q8 hours
35 +/− 5 126 +/− 21
LCMS[92] 15 mg/m2 3hour inf
q8 hours
35 127-135
HPLC[90] 30 mg/m2 40 to 60
hours inf
10 to 15 -
5-AZA-CdR, 5-aza-2-deoxycytidine; inf, infusion; LCMS, liquid
chromatography/mass spectrometry.
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and 80 mg/kg were explored. When 5-AZA-CdR was given
at doses of 1 to 25 mg/m2/hour for 12 to 30 hours, only
minor responses were observed. At a dose of 25 to 50 mg/
m2/hour for 36 to 44 hours (2.35 to 4.70 μM), two
complete remissions (CRs) were observed among nine
patients. The authors reported a significant reduction of
circulating blasts at all dose levels. In addition, 5-AZA-CdR
cleared the CSF of two acute lymphocytic leukemia (ALL)
patients with central nervous system involvement. No max-
imum tolerated dose (MTD) was reported. The major tox-
icity was myelosuppression that occurred at doses of 36 to
80 mg/kg infused over 36 to 44 hours. In a continuation of
this study, 27 pediatric acute leukemia patients were treated
with a continuous infusion of 5-AZA-CdR at doses ranging
from 37 to 80 mg/kg over 36 to 60 hours. The predicted
steady-state plasma level of 5-AZA-CdR for this schedule is
1.5 to 5 μM. The overall objective response rate was 37%
(33% in ALL patients and 50% in AML patients) [97]. In
this phase I trial, the MTD was estimated to be in the range
of 1,500 to 2,250 mg/m2 [7,97]. Despite promising out-
comes, the development of the drug was discontinued due
to the risk of prolonged myelosuppression in patients with
advanced leukemia [98].
Several clinical trials investigating different drug dosing
schedules of 5-AZA-CdR demonstrated significant clinical
benefits in the treatment of patients with MDS and AML
[11,56,98-100]. 5-AZA-CdR was initially investigated in a
trial of 10 MDS patients [101]. Patients were treated with
5-AZA-CdR at a daily dose of 45 mg/m2 divided into
three four-hour infusions for three days (six patients) or
as a continuous infusion of 50 mg/m2 for three days (four
patients). 5-AZA-CdR induced an overall response rate of
50% with a complete hematologic response in 40% of
patients. A subsequent clinical trial reported similar re-
sponse rates [102]. The finding that low doses of 5-AZA-
CdR (3 mg/kg/cycle) showed activity in patients with
sickle cell anemia, by re-expressing the fetal globin gene
[10], led to the suggestion that low-dose use of 5-AZA-
CdR could be effective against this disease, as well as
MDS [18,103]. This hypothesis was evaluated in a phase I
study with various low-dose levels of 5-AZA-CdR inpatients with MDS or leukemia [11]. Unlike traditional
phase I studies, the goal of this study was not to determine
the MTD, but to determine the optimal biologic dose of
this drug based on the response and other related para-
meters. Forty-eight patients were enrolled, the majority
with AML. Responses were observed at the intermediate
dose level of 15 mg/m2 daily × 10 days (150 mg/m2/course).
As a result, this dose level was investigated in 11 additional
patients. Of the nine responders, eight achieved CR after
one cycle of 5-AZA-CdR. Hematologic toxicities were com-
mon but difficult to distinguish from the underlying dis-
ease. Non-hematologic side effects were uncommon.
Pharmacodynamic studies revealed that dose-dependent
decreases in DNA methylation reached a plateau at ap-
proximately 150 to 200 mg/m2/course [104]. Hypomethyla-
tion was observed for the p15 tumor-suppressor gene, but
there was no clear correlation between hypomethylation of
this gene and the overall response [104]. These results sug-
gested that response to 5-AZA-CdR can occur at levels
below the MTD and that prolonged exposure increases the
response.
5-AZA-CdR was approved by the Food and Drug
Administration (FDA) in 2006 for the treatment of
MDS on the basis of a phase III multicenter trial
[105]. In this trial, 170 patients with MDS were rando-
mized to receive either i.v. 5-AZA-CdR 15mg/m2 over
three hours every eight hours for three consecutive days
(135 mg/m2/course) every six weeks or the best support-
ive care (BSC). The overall response rate for the 5-AZA-
CdR arm was 30%, compared with 7% for the BSC arm
(P <0.001). The median duration of the response was 41
weeks with no difference in the time to AML progression
compared with the BSC [105]. Similarly, the European
Organization for Research and Treatment of Cancer and
the German MDS Study Group conducted a large phase
III multicenter trial that randomized 233 elderly patients
with higher-risk MDS to receive either i.v. 5-AZA-CdR
15 mg/m2 over three hours every eight hours for three
consecutive days (135mg/m2/course) every six weeks or the
BSC [106]. This trial reported a 34% overall response rate
with 5-AZA-CdR and an improvement in the progression-
free survival (0.55 versus 0.25 years; P = 0.004) compared
with the findings for the BSC group.
The time to AML progression and overall survival,
however, did not differ significantly between the two
groups. The main adverse effect due to 5-AZA-CdR
treatment appears to be myelosuppression, including se-
vere neutropenia, thrombocytopenia, and anemia. The
incidence of myelosuppression, however, decreases in
responding patients with the continuation of therapy.
Grade 3/4 non-hematologic toxicity is rare and usually
clinically insignificant.
MDS patients who fail 5-azacytidine treatment can re-
spond to 5-AZA-CdR. In a study of 14 MDS patients
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therapy, low-dose 5-AZA-CdR (20 mg/m2/day i.v. over 5
days) was investigated [107]. The overall response rate
was 28% (four patients), including CRs in three patients.
In another study, the activity of 5-AZA-CdR was
tested in 27 elderly patients with AML, MDS, or CML
[108]. One CR was observed with the dose of 500 mg/
m2/24 hours for the three-day schedule (estimated
plasma drug concentration, 2 μM). There were five par-
tial remissions. In this mostly ARA-C–resistant patient
group, the efficacy of 5-AZA-CdR was unquestionable.
Myelosuppression, however, was prolonged up to 42
days. At the time of this study, G-CSF injections were
not available to accelerate bone marrow recovery.
In another study, the activity of 5-AZA-CdR was
tested in 27 elderly patients with AML, MDS, or chronic
myeloid leukemia (CML) [56]. 5-AZA-CdR was adminis-
tered at doses of 30 to 90 mg/m2 for AML patients as a
four-hour i.v. infusion three times a day for three days.
The overall response rate of 45% was encouraging in this
group of patients with refractory disease. On the basis of
these promising outcomes, the same research group
tested 5-AZA-CdR at higher doses in a cohort of 12
patients with AML [109]. The overall response rate was
around 40% in this group of patients with poor progno-
ses. The promising results achieved in these two studies
support the rationale for further investigations of 5-
AZA-CdR in AML patients.
In a study of elderly AML patients, 5-AZA-CdR was
administered at 20 mg/m2/day for five days every four
weeks [110]. The overall response rate was around 26%.
The median time to response was three cycles. Toxicities
were similar to those in the previous studies at this dose
level. In the study that led to the approval of 5-AZA-
CdR for MDS by the FDA, a retrospective detailed inves-
tigation of bone marrow revealed that 12 patients with
AML were misdiagnosed as MDS. Nine of these patients
were randomly assigned to receive 5-AZA-CdR, and the
response rate in this subgroup for 5-AZA-CdR was 56%
[105]. Several studies have evaluated the combination of
5-AZA-CdR with other anti-cancer agents [111]. In this
review, we have focused primarily on 5-AZA-CdR
monotherapy.
Currently, there is no established care for AML
patients who are not eligible to receive standard induc-
tion chemotherapy due to poor performance status. A
phase III study that enrolled 485 patients who were at
least 65 years of age with newly diagnosed, de novo, or
secondary AML and intermediate or unfavorable risk
cytogenetics was performed [112]. 5-AZA-CdR was
given at a dose of 20 mg/m2/day as a one-hour infusion
for five consecutive days every four weeks (estimated
drug plasma concentration of 2 μM for one hour).
Patients on 5-AZA-CdR had a median overall survival(OS) of 7.7 months, compared with 5 months in the
control arm with a hazard ratio of 0.85. The stratified
log-rank analysis, however, did not demonstrate a statis-
tical significance between the groups. Subsequently, an
unplanned OS analysis with one year of additional
follow-up demonstrated the same improvement in me-
dian OS with a nominal P value of 0.037 (data on file).
As of February 2012, the FDA concluded, based on stat-
istical analysis, that 5-AZA-CdR does not appear to im-
prove survival in older patients with AML [113]. The
correlation of clinical responses and plasma levels of 5-
AZA-CdR in hematologic malignancies and in MDS is
summarized in Tables 6 and 7, respectively.
5-Aza-CdR in the treatment of solid tumors
The anticancer activity of 5-AZA-CdR was studied in
patients with refractory and metastatic solid tumors. In
a phase I study of 5-AZA-CdR, the efficacy and toxicity
of the drug were also explored in three children with
metastatic solid tumor [7]. 5-AZA-CdR was given by
continuous infusion. At doses in the range of 0.75 to 80
mg/kg for 12 to 44 hours, only limited activity was
observed.
In a study of refractory metastatic prostate cancer
patients, treatment with one-hour infusions of 75 mg/
m2 5-AZA-CdR, every eight hours for three doses stabi-
lized the disease in 2 of 12 patients with an evaluable
responses [114]. In another study, a seven-day continu-
ous infusion of 5-AZA-CdR was investigated in patients
with refractory solid tumors at a daily dose of 2 mg/m2
[115]. The findings of this study demonstrated that gen-
omic DNA methylation reverted to baseline levels by 28
to 35 days after the start of 5-AZA-CdR treatment. No
objective responses were observed, however, probably
due to the very low concentrations of 5-AZA-CdR in the
body fluids. Only one patient with metastatic ovarian
cancer and one patient with renal carcinoma had stable
disease.
In a pilot phase I/II study performed in 15 patients
with stage III/IV metastatic non-small cell lung cancer
(NSCLC), 5-AZA-CdR was administered over eight
hours as a continuous infusion at doses of 200 to 660
mg/m2 [116]. The steady-state plasma level of 5-AZA-
CdR was estimated to range from 1 to 5 μM. Three
patients survived beyond 15 months, indicating that
relatively high doses of 5-AZA-CdR had anti-tumor ac-
tivity. One patient who received five cycles of 5-AZA-
CdR survived for seven years. The hematopoietic toxicity
of this schedule was acceptable. These interesting results
warrant further investigation of 5-AZA-CdR for the
treatment of NSCLC using longer durations of infusions
(18 to 24 hours).
In summary, treatment of solid tumors with 5-AZA-
CdR led to only limited responses. Notably, however, the













AMLa ind:135 mg/m2 main:20 mg/m2 1 to 72 hours 0.12 to 1.25 μM 0.12 to 90 26 [143]
AML 20 mg/m2 1 hour 1.25 μM 1.25 25 (24) [110]
AML 20 mg/m2 1 hour 1.25 μM 1.25 64 (47) [144]
CMML 15 mg/m2 3 to 4 hours 0.24 to 0.31 μM 0.72 to 1.24 25(11) [105,145,146]
AML 20 mg/m2 1 hour 1.25 μM 1.25 67 (26) [147]
CML 50 to 100 mg/m2 6 hour 0.52 to 1.0 μM 3.12 to 6.0 B28(10),A55(23),
C63(13)
[148]
CML 50 to 100 mg/m2 6 hours 0.52 to 1.0 μM 3.12 to 6.0 53 (0) [121,122]
CML 50 to 100 mg/m2 6 hours 0,52 to 1,0 μM 3.12 to 6.0 84 (10) [121,122]
AMLb 90 mg/m2 4 hours 1.41 μM 5.64 100 (100) [149]
AMLc 125 to 250 mg/m2 6 hours 1.3 to 2.6 μM 7.8 to 15.6 44 (44) [150]
AMLd 125 to 250 mg/m2 6 hours 1.3 to 2.6 μM 7.8 to 15.6 41 (41) [151]
AMLd 125 to 250 mg/m2 6 hours 1.3 to 2.6 μM 7.8 to 15.6 82(73) [137]
AML 250 to 500 mg/m2 6 hours 2.61 to 5.2 μM 15.66 to 31.2 20 (0) [137]
AML 270 to 360 mg/ m2/day t.i.d. 4 hours 4.2 to 5.6 μM 16.8 to 22.4 40 (30) [109]
AML, ALL,
CML
300 to 500 mg/m2/day c. i.v. 24 to 120
hours
0.16 to 1.3 μM 3.84 to 156.0 26 (4) [108]
AML, ALL 37 to 80 mg/kg c.i.v. 36 to 60
hours
1.4 to 5.15 μM 50.4 to 309.0 37 (22) [97]
AML,ALL 0.75 to 80 mg/kg conti.i.v. 12 to 44
hours
0.04 to 15 μM 9.0 to 660.0 14 (9) [7]
ain combination with ATRA; bin combination with daunorubicin; cin combination with idarubicin; din combination with amsacrine. 1 μM= 228 ng/ml. 5-AZA-CdR,
5-aza-2′-deoxycytidine; A, accelerated; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATRA, all trans retinoic acid; AUC, area under the curve;
B, blastic; C, chronic; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete remission; ORR, overall response rate.
Table 7 Correlation of clinical responses and plasma




















i.v t.i.d. x 3d
4 hours 0.23 μM 20(15) [123]
15 mg/m2
t.i.d. q3d
3 hours 0.31 μM 17 (9) [105]
1 μM = 228 ng/ml. 5-AZA-CdR, 5-aza-2′-deoxycytidine; CR, complete remission;
MDS, myelodysplastic syndrome; ORR, overall response rate.
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time to the drug in solid tumor studies were suboptimal
when compared with the results achieved with higher
concentrations in both in vitro and in vivo animal stud-
ies. As clearly demonstrated in the mouse model, doses
of 5-AZA-CdR must be intensified to realize potent anti-
tumor activity [60].
Correlation of the plasma level of 5-AZA-CdR with
chemotherapeutic action
In vitro colony-forming assays of leukemic cells revealed
that there is a significant correlation among the concentra-
tion of 5-AZA-CdR, the exposure time, and its anticancer
and demethylating effects [44,59]. A study on human mye-
loid, T-cell and B-cell lines, revealed that 10 μM 5-AZA-
CdR for one hour produced a loss of clonogenicity of these
cells lines that was 33%, 50%, and 49%, respectively. These
observations confirm the S-phase specificity of 5-AZA-
CdR, that is, only cells in S-phase, but not G1 and G2, are
targets of this chemotherapy. During a one-hour treatment
approximately 50% of the cells are present in S phase. With
an exposure time of 24 hours, 1 μM 5-AZA-CdR produced
96%, >98%, and 100% losses of clonogenicity, respectively,
for the three leukemic cell lines. These findings indicatethe importance of the exposure time to 5-AZA-CdR,
which should be long enough to permit the transit of all
leukemic cells into S-phase. The doubling time of the cell
lines was 20 to 24 hours [117].
The therapeutic and toxic effects of 5-AZA-CdR were
investigated in mice with L1210 leukemia. The authors of
one study concluded that a treatment duration of 24
hours, giving a 5-AZA-CdR plasma level of around 2 μM,
would be most desirable for maximum cell kill [117]. In
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5-AZA-CdR was estimated to be 20 mg/kg administered
as an 18-hour infusion [60]. The estimated plasma con-
centration of 5-AZA-CdR for this infusion was approxi-
mately 3 μM.
The antileukemic activity of 5-AZA-CdR was also studied
in the Brown Norway rat leukemia model, which is a good
model of human AML [4]. A dose–response relationship
was observed for 5-AZA-CdR for doses up to 50 mg/kg
(administered every 12 hours × 3) in this rat model. This
dose of 5-AZA-CdR produced a 100% increase in survival
time. In this rat model of AML, 5-AZA-CdR was more ef-
fective than ARA-C (at a dose of 200 mg/kg per treatment).
It is interesting that both 5-AZA-CdR and ARA-C reduced
the number of normal hematopoietic stem cells in the bone
marrow by 30% to 40% at a dose of 50 mg/kg, with no fur-
ther reduction at higher doses (250 mg/kg). This is a clear
indication that the resting normal hematopoietic stem cells
survive intensive doses of S-phase–specific agents (adminis-
tered over an interval of 24 hours) due to the presence of
resting non-proliferating hematopoietic stem cells [4].
Studies of the antineoplastic action of 5-AZA-CdR in
mouse models of solid tumors provide some insight into
the importance of the dose schedule. The in vivo/in vitro
EMT6 tumor model is an excellent tool to study the
pharmacodynamics of antineoplastic agents [118]. In this
model, EMT6 tumor cells from cell culture are injected
subcutaneously (s.c.) into mice, and chemotherapy is
administered when the tumor size is approximately 3 to
5 mm. After chemotherapy, the tumor is excised and
trypsinized, and single-cell suspensions are plated in
Petri dishes. Cell survival after chemotherapy is quanti-
fied by comparing the number of colonies to the number
with controls. Using this assay, 5-AZA-CdR at a dose of
30 mg/kg as an 18-hour infusion markedly reduced the
proliferative potential of the tumor stem cells [60]. The
estimated plasma level of 5-AZA-CdR in this treatment
was in the range of 4 μM. These preclinical results illus-
trate the importance of using intensive chemotherapy
with 5-AZA-CdR to obtain a good antitumor response.
Hematopoietic toxicity of 5-Aza-CdR
The major side effect of 5-AZA-CdR is myelosuppression.
In patients with advanced hematologic malignancies, it is
difficult to fully evaluate the hematopoietic toxicity of
5-AZA-CdR due to the presence of a large number of ab-
normal cells in the bone marrow, which can interfere with
recovery after chemotherapy. Tumor patients without the
presence of malignant cells in the bone marrow are good
candidates for the evaluation of hematopoietic toxicity on
‘normal bone marrow’. Patients with lung cancer without
prior chemotherapy treated with 660 mg/m2 5-AZA-CdR
as an eight-hour infusion exhibited significant recovery of
the white blood cell count at approximately day 35 [116].In patients with advanced acute leukemia, the recovery
of the granulocyte count (>500/μl) after an intensive
dose of 5-AZA-CdR occurred at about day 45 [97]. This
observation suggests that the interval between cycles of
5-AZA-CdR therapy should be six weeks to permit ad-
equate recovery of the granulocyte count. At low doses of
5-AZA-CdR (15 to 20 mg/m2), the drug is well tolerated
in patients with MDS, and the primary hematological tox-
icity is transient neutropenia, which is predictable and
manageable [92,111,119,120].
In a study of patients with CML, 5-AZA-CdR was admi-
nistered at a dose of 500 to 1,000 mg/m2 over five days
and prolonged neutropenia was the major side effect
[121,122]. At doses of 75 to 100 mg/m2 delivered over six
hours every 12 hours for 10 doses, the median time to
neutrophil recovery above 500/μl was 50 (total dose of
1,000 mg/m2/cycle) or 45 days (total dose of 750 mg/m2/
cycle), respectively.
Discussion
5-AZA-CdR is an effective epigenetic drug for the treat-
ment of hematologic malignancies. The clinical efficacy of
5-AZA-CdR is due to its demethylating epigenetic action,
which reactivates tumor suppressor genes silenced by
DNA methylation. Low-dose 5-AZA-CdR (20 mg/m2
one-hour infusion x five days or 15 mg/m2 four-hour infu-
sion q8 h × three days) can produce CRs in patients with
MDS and AML [99,123]. These low dose schedules cause
less toxicity than intensive doses of 5-AZA-CdR. This is
especially important for older patients with a poor per-
formance status who are not good candidates for intensive
therapy with 5-AZA-CdR. The interesting responses to
low-dose 5-AZA-CdR suggest that leukemic stem cells are
very sensitive to low concentrations of 5-AZA-CdR, an
indication of the immense chemotherapeutic potential of
this drug.
Recent preclinical reports indicate that very low dose
5-AZA-CdR administered frequently (two to three
times/week) also has the potential to be an effective
form of therapy for cancer. One reason for the failure of
cytotoxic chemotherapy is that malignant cells can be
resistant to the induction of apoptosis due to a non-
functional p53 pathway as a result of mutations or dele-
tions [124]. However, the genes that program terminal
differentiation in these apoptosis-resistant malignant
cells can be silenced by epigenetic mechanisms, such as
DNA methylation, and reactivated by non-toxic doses of
5-AZA-CdR. This same treatment maintains the self-
renewal of normal hematopoietic stem cells by preventing
repression of stem cell genes by differentiation-inducing
stimulus and induces differentiation of AML cells [54].
For these reasons the very low dose 5-AZA-CdR does not
produce pronounced granulocytopenia as observed with
intense doses of this agent.
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low-dose 5-AZA-CdR. 5-AZA-CdR inhibits in vitro prolif-
eration, decreases colony formation and induces myeloid
differentiation of p53-null AML cells [125]. These observa-
tions were confirmed using fresh AML cells from a patient.
The AML cells were transplanted into NSG immunosup-
pressed mice and treated with a s.c. injection of 5-AZA-
CdR (0.2 mg/kg three times/week for two weeks, then
once/week). This very low dose 5-AZA-CdR was much
more effective in prolongation of the survival time of the
leukemic mice than an intense dose of ARA-C (75 mg/kg
per day intraperitoneally for five days). The proof of
principle of the very low-dose 5-AZA-CdR was also con-
firmed in a clinical trial in MDS patients with high-risk
cytogenetics [126]. 5-AZA-CdR 3.5 to 7 mg/m2 adminis-
tered one to three times/week produced an overall re-
sponse of 84% (CR + hematologic improvement + stable
disease), which is remarkable. Complete cytogenetic remis-
sions were observed in 50% of the patients. It will be inter-
esting to see if this non-toxic differentiation therapy with
5-AZA-CdR will be effective in older AML patients who
are not candidates for cytotoxic chemotherapy.
One limitation of the low dose 5-AZA-CdR for the
treatment of AML or MDS is the problem of eradicating
malignant cells in the liver or spleen due to the high
activity of cytidine deaminase. Deamination of 5-AZA-
CdR can reduce its concentration to sub-therapeutic
levels in these organs. The use of an inhibitor of cytidine
deaminase, such as tetrahydrouridine, in combination
with 5-AZA-CdR has the potential to overcome this
problem [127]. The proof of principle of this approach
was demonstrated in a murine xenotransplant model of
AML where tetrahydrouridine produced a marked en-
hancement of the antineoplastic activity of 5-AZA-CdR
[128]. The combination of these agents merits a high
priority for clinical investigation in patients with
hematologic malignancies.
Preclinical studies indicate that very low-dose 5-AZA-
CdR also has the potential to be an effective treatment for
tumors with a favorable epigenetic signature. As an ex-
ample, human renal carcinoma cells derived from a patient
were inoculated s.c. into nude mice followed by treatment
with low dose 5-AZA-CdR (0.2 mg/kg s.c. × 3/week) [129].
This low dose therapy was very effective in reducing tumor
growth and did not produce leukopenia. This low dose
5-AZA-CdR, in combination with tetrahydrouridine to in-
hibit cytidine deaminase, was also very effective in inhibit-
ing the growth of murine melanoma tumors in mice [130].
The low dose chemotherapy did not produce leukopenia
or reduction in body weight. 5-AZA-CdR was also shown
to induce differentiation of both human and murine mel-
anoma cell lines.
These observations on very low 5-AZA-CdR therapy
of leukemia and tumors were confirmed by Tsai et al.[131] using a different dose-schedule. These investigators
showed that low dose 5-AZA-CdR (72-hour exposure)
reduced colony formation of AML cells from patients, but
not the normal hematopoietic stem cells colony-forming
units-granulocyte macrophage (CFU-GM). The low dose
5-AZA-CdR (0.1 μM, 72 hours ex vivo) followed by 7 to
14 days drug-free media was also shown to decrease
tumorigenicity in mouse tumor xenografts.
In summary, the very low dose 5-AZA-CdR preclin-
ical studies showed that this type of treatment could
produce a loss in the self-renewal potential of cancer
stem cells due to the increase in the expression of genes
that suppress malignancy. These epigenetic changes are
maintained in the target cells after drug removal and
accumulate with each low dose treatment until there is
a complete loss of cancer stem cell potential. The low
dose chemotherapy merits clinical investigation in
patients with cancer. The very low dose 5-AZA-CdR
may also have the potential to maintain CR in patients
with leukemia and arrest malignant progression in
patients with solid tumors. For cancer patients with
poor performance status the very low dose 5-AZA-CdR
therapy may be a good option to improve the quality of
life rather than the use of only supportive therapy or no
treatment.
Some patients with cancer may not respond or show
disease progression on the low dose-schedule 5-AZA-
CdR. This may be due to fact that: a) the cancer may have
an epigenetic/genetic signature that is not predisposed to
the induction of terminal differentiation by low dose
5-AZA-CdR; b) the target cancer cells may have a low
level of deoxycytidine kinase, the enzyme that activates
the prodrug, 5-AZA-CdR [132]; c) the cancer cells may be
in anatomic sanctuaries that have low penetration of
5-AZA-CdR (for example, CSF, testis, tumors with a lim-
ited blood supply [133]). The concentration of 5-AZA-
CdR in these sanctuaries is too low to eliminate the cancer
stem cells; d) the cancer cells may be in a biochemical
sanctuary that contains high levels of cytidine deaminase
(for example, liver, spleen); e) drug resistance develops
more rapidly after repetitive treatments with low-dose
chemotherapy; f ) because 5-AZA-CdR is a cell cycle-
specific agent, a one- to four-hour infusion of this agent
only targets cancer cells in S-phase, whereas cells in G1
and G2 phases escape the chemotherapeutic action of this
analog during short-term treatment. A long interval (12 to
24 hours) between infusions can also permit leukemic
stem cells to pass through the S-phase cell cycle without
exposure to 5-AZA-CdR and, thus, escape its antileuke-
mic action. This possibility was demonstrated in a preclin-
ical study on leukemia using the S phase–specific drug
ARA-C [134].
One approach to overcome these caveats is to use in-
tensive chemotherapy with 5-AZA-CdR administered as
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objective is of high priority and involves determination
of the optimal plasma level of 5-AZA-CdR and duration
of treatment that can eliminate leukemic stem cells in
these sanctuaries. The in vitro data on colony assays of
human leukemic cell lines indicate that a concentration
of 5-AZA-CdR in the range of 1 to 2 μM for the dur-
ation of the cell cycle of the leukemic cells has the ability
to completely eliminate their proliferative potential. An-
other approach is to use 5-AZA-CdR in combination
with an inhibitor of cytidine deaminase, such as tetrahy-
drouridine or zebularine, to target the leukemic cells in
the biochemical sanctuaries [135,136]. An additional ap-
proach is to use 5-AZA-CdR in combination with a bio-
chemical modulator, such as 3-deazauridine, to eliminate
drug-resistant leukemic cells due to a deficiency in de-
oxycytidine kinase [132]. Cancer cells deficient in deoxy-
cytidine kinase are very sensitive to the cytotoxic action
of 3-deazauridine [132].
One of the key points concerning intensive-dose ther-
apy with 5-AZA-CdR is the fact that it produces delayed
and prolonged myelosuppression. Several investigators
have used intensive-dose 5-AZA-CdR in patients with
advanced leukemia and observed that most of these
patients with a good performance status recovered from
the hematopoietic toxicity. These early studies were per-
formed before the clinical use of granulocyte colony
stimulating factors to accelerate the recovery from myelo-
suppression. Some examples of the dose schedules of
intensive-dose 5-AZA-CdR that were used are: total dose
of 2,479 mg/m2 as a 60-hour i.v. infusion; 500 mg/m2 as a
6-hour infusion every 12 hours × 5 days for a total dose of
5,000 mg/m2; and a daily dose of 300 to 500 mg/m2 as a
24 to 120 hour infusion [97,108,137]. The estimated
plasma level of 5-AZA-CdR in these studies ranged from
1 to 3 μM. The hematopoietic toxicity produced by inten-
sive doses of 5-Aza-CdR can also be predicted from its
comparative pharmacology with the related deoxycytidine
analogue, ARA-C. Both 5-AZA-CdR and ARA-C are
S-phase–specific agents. They have identical metabolism,
and their antineoplastic action is due to their incorpor-
ation into DNA, but their molecular mechanisms of action
differ. 5-AZA-CdR inhibits DNA methylation, whereas
ARA-C potently inhibits DNA replication. Because they
target the same cells (proliferating cells in S phase), they
should produce a similar pattern of hematopoietic toxicity.
Most leukemic patients in CR with a good performance
status recover from the hematopoietic toxicity produced by
very high-dose ARA-C (up to 6,000 mg/m2/day for four
days; total dose 24,000 mg/m2) [138]. These observations
provide a rationale for intensive doses of 5-AZA-CdR in
the range of 1,000 mg/m2/day in leukemic patients in CR
without encountering unacceptable hematologic toxicity
for patients with a good performance status. The recoveryfrom granulocytopenia after 5-AZA-CdR is approximately
two weeks longer than that after ARA-C [97]. This is prob-
ably due to the delayed epigenetic action of 5-AZA-CdR
on normal hematopoietic stem cells compared with the
acute cell kill produced by ARA-C. From this point of
view, it is better to use a six-week interval between cycles
of 5-AZA-CdR rather than the four-week interval used for
ARA-C.
It is a remarkable achievement that current chemother-
apy can induce CR in most patients with hematologic ma-
lignancies. The major challenge is maintaining the patients
in CR. Patients in CR are good candidates for experimental
chemotherapy because of their good hematologic status.
From an ethical point of view, high-risk leukemic patients
with an unfavorable karyotype that predicts a poor outcome
are good candidates for intensive therapy with 5-AZA-CdR.
Pharmacokinetic/pharmacodynamic calculations can
be used to estimate the optimal dose for 5-AZA-CdR.
For the initial studies, we recommend a combination of
intensive and low-dose 5-Aza-CdR to treat high-risk
patients with leukemia. For the initial intensive phase,
5-AZA-CdR can be infused at a rate of 30 mg/m2/hour
for days one and two (total dose 1,440 mg/m2/day). This
infusion rate should give a plasma concentration of ap-
proximately 2 μM, shown to be very effective in both
in vitro and in vivo animal studies on leukemia. The
objective of this intensive therapy of 5-AZA-CdR is to
target the most rapidly proliferating leukemic stem cells
and those in anatomic and biochemical sanctuaries. The
intensive phase is followed by a low-dose phase where
5-AZA-CdR is administered on days three and four as a
short infusion at a dose of 30 mg/m2/day. The objective
of this phase is to target cancer stem cells with a long
cell cycle that do not enter the S phase during the first
two days of treatment. Supportive care with granulocyte
colony stimulating factor is recommended to shorten
the duration of granulocytopenia. The interval between
each cycle of therapy should be six weeks to permit ad-
equate recovery from bone marrow toxicity. Modifica-
tions of the proposed dose schedule may be required for
optimization. In subsequent studies, the low-dose phase
of 5-AZA-CdR can be replaced by histone deacetylase
(HDAC) and/or histone methylation inhibitors, which
showed a synergistic interaction against leukemic cells in
preclinical studies [139,140]. It could also be interesting
to design a clinical study in AML patients to see the effi-
cacy and safety of decitabine in combination with prom-
ising novel tyrosine kinase inhibitors such as quizartinib
[141]. Both preclinical and clinical observations indicate
that 5-AZA-CdR has tremendous potential for the treat-
ment of hematologic malignancies. The results of this
proposed clinical trial on 5-AZA-CdR will be of great
interest and will hopefully lead to improved overall sur-
vival of patients with advanced leukemia.
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merits clinical investigation. Most malignancies have a
large number of tumor suppressor genes that are silenced
by aberrant DNA methylation, providing many interesting
targets for 5-AZA-CdR therapy. The preclinical data indi-
cate that all types of tumors are sensitive to 5-AZA-CdR
treatment, including low dose therapy. However, the clin-
ical responses to low-dose 5AZA-CdR in solid tumors are
reported to be very limited. It should be noted, however,
that the estimated plasma levels of 5-AZA-CdR in these
trials was too low. In vitro clonogenic assays using an
exposure time of 24 hours on tumor cells indicate that
low concentrations of 5-AZA-CdR are not very effective.
Our preclinical data on chemotherapy of tumors in the
mouse model suggest that the plasma level of 5-AZA-CdR
should be approximately 3 μM for curative therapy [60].
An example of the potential of intensive doses for tumor
therapy is the pilot stage III/IV NSCLC study where the
patients were administered 5-AZA-CdR (660 mg/m2 as an
eight-hour infusion), which produced a plasma concentra-
tion in the range of 3 μM. This study produced some
promising results: three patients who survived for 15
months and one patient who survived for seven years
[116]. The preclinical data support the possibility of this
type of response and predict that an infusion time longer
than eight hours should be more effective. One major rea-
son for the failure of tumor chemotherapy is the limited
penetration of drugs into tumors [133]. One approach to
overcome this problem is to obtain high plasma concen-
trations of anticancer drugs to enhance their penetration
into tumors. This provides a rationale for the use of
intensive-dose 5-AZA-CdR for the treatment of solid
tumors. S phase–specific drugs can be used at very high
doses for a limited duration without unacceptable side
effects. Patients with metastatic malignancy and poor
prognosis are potentially good candidates for intense
chemotherapy with 5-AZA-CdR. As an initial study, we
suggest a dose schedule of 60 mg/m2/hour administered
as an 18-hour infusion (total dose of 1,080 mg/m2). This
dose schedule will give an estimated steady state plasma
concentration in the range of 4 μM. The interval between
cycles should be six weeks to permit adequate bone mar-
row recovery. Patients treated previously with intensive
cytotoxic chemotherapy are at risk of severe hematopoietic
toxicity and require a minimum of four weeks of recovery
before being eligible for intensive 5-AZA-CdR therapy.
Patients who do not respond to anticancer agents that do
not produce hematopoietic toxicity would also be good
candidates for this investigational therapy. Depending on
the response, the intensive dose schedules for 5-AZA-CdR
may have to be modified for optimization (for example,
increase the dose and/or duration of the infusion; use low
dose 5-AZA-CdR between cycles of intensive doses). The
goal should be to optimize the dose-schedule of 5-AZA-CdR to reveal its potential for tumor therapy. It may also
be possible to increase the effectiveness of this tumor ther-
apy by using a sequential treatment of 5-AZA-CdR fol-
lowed by an inhibitor of histone modification [139,140] or
with a tyrosine kinase inhibitor [142].
Conclusion
Epigenetic changes, such as DNA methylation, play a very
important role in both leukemogenesis and tumorigenesis.
Because these epigenetic changes are very prominent in
cancer cells and are reversible, they are potential targets
for chemotherapy with 5-AZA-CdR. Pharmacodynamic
and pharmacokinetic analysis of 5-AZA-CdR from both
preclinical and clinical data can provide insight toward
optimizing cancer treatment using this interesting epigen-
etic agent.
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